Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/7445
Title: Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension
Authors: PULIDO, TomasADZERIKHO, IgorCHANNICK, Richard N.DELCROIX, MarionGALIE, NazzarenoGHOFRANI, Hossein-ArdeschirJANSA, PavelJING, Zhi-ChengBRUN, Franck-Olivier LeMEHTA, SanjayMITTELHOLZER, Camilla M.PERCHENET, LoicSASTRY, B. K. S.SITBON, OlivierSOUZA, RogerioTORBICKI, AdamZENG, XiaofengRUBIN, Lewis J.SIMONNEAU, Gerald
Citation: NEW ENGLAND JOURNAL OF MEDICINE, v.369, n.9, p.809-818, 2013
Abstract: Background Current therapies for pulmonary arterial hypertension have been adopted on the basis of short-term trials with exercise capacity as the primary end point. We assessed the efficacy of macitentan, a new dual endothelin-receptor antagonist, using a primary end point of morbidity and mortality in a long-term trial. Methods We randomly assigned patients with symptomatic pulmonary arterial hypertension to receive placebo once daily, macitentan at a once-daily dose of 3 mg, or macitentan at a once-daily dose of 10 mg. Stable use of oral or inhaled therapy for pulmonary arterial hypertension, other than endothelin-receptor antagonists, was allowed at study entry. The primary end point was the time from the initiation of treatment to the first occurrence of a composite end point of death, atrial septostomy, lung transplantation, initiation of treatment with intravenous or subcutaneous prostanoids, or worsening of pulmonary arterial hypertension. Results A total of 250 patients were randomly assigned to placebo, 250 to the 3-mg macitentan dose, and 242 to the 10-mg macitentan dose. The primary end point occurred in 46.4%, 38.0%, and 31.4% of the patients in these groups, respectively. The hazard ratio for the 3-mg macitentan dose as compared with placebo was 0.70 (97.5% confidence interval [CI], 0.52 to 0.96; P=0.01), and the hazard ratio for the 10-mg macitentan dose as compared with placebo was 0.55 (97.5% CI, 0.39 to 0.76; P<0.001). Worsening of pulmonary arterial hypertension was the most frequent primary end-point event. The effect of macitentan on this end point was observed regardless of whether the patient was receiving therapy for pulmonary arterial hypertension at baseline. Adverse events more frequently associated with macitentan than with placebo were headache, nasopharyngitis, and anemia. Conclusions Macitentan significantly reduced morbidity and mortality among patients with pulmonary arterial hypertension in this event-driven study. (Funded by Actelion Pharmaceuticals; SERAPHIN ClinicalTrials.gov number, NCT00660179.)
Appears in Collections:Artigos e Materiais de Revistas Científicas - FM/MCP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/09

Files in This Item:
File Description SizeFormat 
art_PULIDO_Macitentan_and_Morbidity_and_Mortality_in_Pulmonary_Arterial_2013.PDF
  Restricted Access
publishedVersion (English)637.05 kBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.